The Study on the Esketamine in the Treatment of Postherpetic Neuralgia
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Herpes zoster (HZ) is an acute herpetic skin disease caused by the reactivation of the
varicella-zoster virus (VZV) latent in the sensory ganglia. Postherpetic neuralgia (PHN)
often occurs after herpes zoster heals and persists for a long time. At present, clinically
anticonvulsants (such as gabapentin, pregabalin) and antidepressants (such as amitriptyline)
are clinically first-line drugs for the treatment of PHN, which are not usually effective to
treat PHN well, as well as to alleviate patients' bad mental symptoms. Esketamine, as a
well-known N-methyl-D-aspartate receptor inhibitor, has both analgesic and antidepressant
effects with extremely few incidence of respiratory depression, delirium, hallucinations,
nausea and vomiting. Therefore, we hypothesize that esketamine could relieve PHN and Anxiety
and depression-like symptoms symptoms in patients with PHN. This study intended to compare
the efficacy of pregabalin, amitriptyline combined with esketamine therapy and pregabalin
combined with amitriptyline therapy for alleviating PHN, and to further explore the
feasibility and safety of esketamine in the treatment of PHN as well as underlying the
mechanism of esketamine on the PHN.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University